# US 2024/0255531 A1 · Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255531 A1
- Document ID: US20240255531A1
- Status: Published application
- Kind: A1
- Application number: 18/289,612
- Filed: 2022-05-06
- Published: 2024-08-01
- Earliest claimed: 2021-05-07
- Assignees: Sphingotec GmbH
- Applicants: Sphingotec GmbH
- Inventors: Deborah BERGMANN; Florian UHLE
- Web page: https://patentgrep.com/patent/US20240255531A1

## CPC

- G01N 33/743: {Steroid hormones}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of selecting critically ill patients for treatment with corticosteroids, by determining the level of ADM-NH2 or fragment thereof in a sample of bodily fluid of the patient, comparing the level of ADM-NH2 or fragment thereof to a pre-determined threshold or to a previously measured level of ADM-NH2 or fragment thereof, and at a value above the threshold appointing a therapy with corticosteroids. A method for corticosteroid therapy guidance and/or stratification in critically ill patients by providing a sample of bodily fluid of the patient, and determining the level of ADM-NH2 or fragment thereof in the sample, and comparing the level of ADM-NH2 or fragment thereof to a pre-determined threshold or to a previously measured level of ADM-NH2 or fragment thereof, wherein the level of ADM-NH2 or fragments thereof is indicative of whether an initiation of a corticosteroid therapy is required.

## Claims

### Claim 1

A method comprising:
treating a subject with corticosteroids,
wherein the level of ADM-NH2 or fragment thereof in a sample of bodily fluid of a patient is more than 20 pg/ml.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein said patients are patients suffering from a disease selected from the group consisting of severe infection, sepsis, septic shock, acute respiratory syndrome (ARDS), community acquired pneumonia (CAP), meningitis, corona virus infection disease, cardiopulmonary bypass surgery (CPB) and cardiac arrest.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

A The method of claim 1, wherein said patient is treated with corticosteroids selected from the group consisting of glucocorticoids or mineralcorticoids.

### Claim 8 (depends on 7)

The method of claim 7, wherein said glucocorticoids are selected from the group consisting of cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone and betamethasone.

### Claim 9 (depends on 7)

The method of claim 7, wherein said mineralcorticoids is fludrocortisone.

### Claim 10 (depends on 3)

The method of claim 3, wherein said Corona Virus is selected from the group consisting of Sars-COV-1, Sars-COV-2, MERS-COV, in particular Sars-COV-2.

### Claim 11 (depends on 1)

The method of claim 1, wherein the bodily fluid is selected from the group consisting of whole blood, serum, and plasma.

### Claim 12 (depends on 1)

The method of claim 1, wherein the level of ADM-NH2 or fragment thereof in said sample is 70 pg/mL.

### Claim 13 (depends on 1)

The method of claim 1, additionally comprising measuring the level of at least one additional biomarker in addition to ADM-NH2 or fragments thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said at least one additional biomarker is selected from the group consisting of D-Dimer, procalcitonin (PCT), C-reactive protein (CRP), lactate, DPP3, penKid, NT-proBNP, BNP, white blood cell count, lymphocyte count, neutrophil count, hemoglobin, platelet count, albumin, alanine transaminase, creatinine, blood urea, lactate dehydrogenase, creatinin kinase, cardiac troponin I, prothrombin time, serum ferritin, interleukin-6 (IL-6), IL-10, IL-2, IL-7, interferon gamma (IF-γ), tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (GCSF), IP-10, MCP-1, and MIP-1α.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

A sample comprising:
bodily fluid from a subject and a capture binder, wherein said capture binder is the product a process comprising:
fusing spenocytes from a mouse immunized with a peptide-BSA-conjugate and cells of a myeloma cell line
screening for capture binders which bind to ADM-NH2 or fragment thereof,
wherein said subject has been diagnosed as critically ill, and
wherein the level of ADM-NH2 or fragment thereof in said sample is more than 20 pg/ml.

### Claim 18 (depends on 1)

The method of claim 1, wherein the level of ADM-NH2 or fragment thereof in said sample is 40 pg/mL.
